New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant...

Full description

Bibliographic Details
Main Authors: Haitang Yang, Shun-Qing Liang, Ralph A. Schmid, Ren-Wang Peng
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
lung cancer
KRAS
mitogen-activated protein kinases
heterogeneity
targeted therapy
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00953/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00953/full

Similar Items